RECORD // Company

Bicara Therapeutics Inc.

Built 2026-11-21T23:57:54Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Bicara Therapeutics · Ctgov · exact name match to 'Bicara Therapeutics Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • BICARA THERAPEUTICS INC. · East licences · same registered legal name as 'Bicara Therapeutics Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001628280-26-072169

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-71,249,0003 months ended 2026-09-3010-Q2026-11-090001628280-26-0721692026-11-21 23:57 UTCReport an error
Cash and cash equivalents$82,021,000at 2026-09-3010-Q2026-11-090001628280-26-0721692026-11-21 23:57 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0002023658
Ticker
BCAX
CUSIP
055477103
Record ID
sx:sec:0002023658

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

28 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-10SEC EDGAR company profile2026-11-21 23:57 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-10SEC EDGAR company profile2026-11-21 23:57 UTCReport an error
State of incorporationDE2026-11-10SEC EDGAR company profile2026-11-21 23:57 UTCReport an error
Fiscal year end (MMDD)12312026-11-10SEC EDGAR company profile2026-11-21 23:57 UTCReport an error
Business address116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 021162026-11-10SEC EDGAR company profile2026-11-21 23:57 UTCReport an error
ExchangesNasdaq2026-11-10SEC EDGAR company profile2026-11-21 23:57 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-137,950,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 23:57 UTCReport an error
Total assets (at 2025-12-31)$430,994,0002025-12-3110-K, XBRL Assets2026-11-21 23:57 UTCReport an error
Stockholders' equity (at 2025-12-31)$401,452,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 23:57 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$96,685,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 23:57 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-106,834,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 23:57 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$280,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 23:57 UTCReport an error
Operating lease liabilities (at 2025-12-31)$1,710,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 23:57 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-09)On November 9, 2026, Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and other business updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the…2026-11-09SEC EDGAR 8-K 0001628280-26-071886 (text as filed, excerpt)2026-11-21 23:57 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-08-25)On August 21, 2026, Bicara Therapeutics Inc. (the “Company”) entered into a Sub-Sublease Agreement (the “Sublease”) with Wayfair LLC, as sublandlord (the “Sublandlord”), pursuant to which the Company, as subtenant, will lease approximately 35,090 square feet of office space for new corporate headquarters to be located at 10 St. James Avenue, Boston, Massachusetts 02116. The Sublease term commences on the later of (i) October 1, 2026 and (ii) the date of full execution of a consent between the Company, the Sublandlord, Liberty Mutual Insurance Company (as landlord) and MT Back Bay One LLC (as overlandlord) (the “Commencement Date”). The base rent under the Sublease Agreement is $105,279 per…2026-08-25SEC EDGAR 8-K 0001628280-26-058937 (text as filed, excerpt)2026-11-21 23:57 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-11)On August 11, 2026, Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and other business updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities…2026-08-11SEC EDGAR 8-K 0001628280-26-055500 (text as filed, excerpt)2026-11-21 23:57 UTCReport an error
8-K Item 5.02, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; (filed 2026-07-28)Compensatory Arrangements of Certain Officers. Resignation of Kiran Mazumdar-Shaw On July 23, 2026, Kiran Mazumdar-Shaw resigned from the Board of Directors (the “Board”) of Bicara Therapeutics Inc. (the “Company”) and her position on the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective as of July 28, 2026. Ms. Mazumdar-Shaw’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. Appointment of Jeremy Bender, Ph.D. and Christy Oliger On July 26, 2026, upon the recommendation of the Nominating and…2026-07-28SEC EDGAR 8-K 0001628280-26-049937 (text as filed, excerpt)2026-11-21 23:57 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-07-28)On July 28, 2026, the Company issued a press release titled “Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors.” A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth under Item 7.01, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.2026-07-28SEC EDGAR 8-K 0001628280-26-049937 (text as filed, excerpt)2026-11-21 23:57 UTCReport an error
Largest institutional holder #1 (13F as filed): RA CAPITAL MANAGEMENT, L.P.$215,430,4322026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:57 UTCReport an error
Largest institutional holder #2 (13F as filed): Siren, L.L.C.$166,352,1792026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:57 UTCReport an error
Largest institutional holder #3 (13F as filed): Vestal Point Capital, LP$155,872,5002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:57 UTCReport an error
Largest institutional holder #4 (13F as filed): Deep Track Capital, LP$121,729,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:57 UTCReport an error
Largest institutional holder #5 (13F as filed): BlackRock, Inc.$114,249,7842026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:57 UTCReport an error
Largest institutional holder #6 (13F as filed): Jupiter Topco LLC$93,957,1742026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:57 UTCReport an error
Largest institutional holder #7 (13F as filed): RED TREE MANAGEMENT, LLC$93,924,8202026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:57 UTCReport an error
Largest institutional holder #8 (13F as filed): TPG GP A, LLC$89,379,5182026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:57 UTCReport an error
Largest institutional holder #9 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$65,812,0122026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:57 UTCReport an error
Largest institutional holder #10 (13F as filed): STATE STREET CORP$60,832,4352026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 23:57 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.